Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Lipid Res ; 61(2): 159-177, 2020 02.
Article in English | MEDLINE | ID: mdl-31818878

ABSTRACT

Bile acids (BAs) serve multiple biological functions, ranging from the absorption of lipids and fat-soluble vitamins to serving as signaling molecules through the direct activation of dedicated cellular receptors. Synthesized by both host and microbial pathways, BAs are increasingly understood as participating in the regulation of numerous pathways relevant to metabolic diseases, including lipid and glucose metabolism, energy expenditure, and inflammation. Quantitative analyses of BAs in biological matrices can be problematic due to their unusual and diverse physicochemical properties, making optimization of a method that shows good accuracy, precision, efficiency of extraction, and minimized matrix effects across structurally distinct human and murine BAs challenging. Herein we develop and clinically validate a stable-isotope-dilution LC/MS/MS method for the quantitative analysis of numerous primary and secondary BAs in both human and mouse biological matrices. We also utilize this tool to investigate gut microbiota participation in the generation of structurally specific BAs in both humans and mice. We examine circulating levels of specific BAs and in a clinical case-control study of age- and gender-matched type 2 diabetes mellitus (T2DM) versus nondiabetics. BAs whose circulating levels are associated with T2DM include numerous 12α-hydroxyl BAs (taurocholic acid, taurodeoxycholic acid, glycodeoxycholic acid, deoxycholic acid, and 3-ketodeoxycholic acid), while taurohyodeoxycholic acid was negatively associated with diabetes. The LC/MS/MS-based platform described should serve as a robust, high-throughput investigative tool for studying the potential involvement of structurally specific BAs and the gut microbiome on both physiological and disease processes.


Subject(s)
Bile Acids and Salts/analysis , Diabetes Mellitus, Type 2/metabolism , Gastrointestinal Microbiome , Animals , Bile Acids and Salts/chemistry , Case-Control Studies , Chromatography, Liquid , Diabetes Mellitus, Type 2/microbiology , Female , Healthy Volunteers , Humans , Male , Mice , Mice, Inbred C57BL , Quality Control , Tandem Mass Spectrometry
2.
J Clin Invest ; 129(1): 373-387, 2019 01 02.
Article in English | MEDLINE | ID: mdl-30530985

ABSTRACT

BACKGROUND: l-Carnitine, an abundant nutrient in red meat, accelerates atherosclerosis in mice via gut microbiota-dependent formation of trimethylamine (TMA) and trimethylamine N-oxide (TMAO) via a multistep pathway involving an atherogenic intermediate, γ-butyrobetaine (γBB). The contribution of γBB in gut microbiota-dependent l-carnitine metabolism in humans is unknown. METHODS: Omnivores and vegans/vegetarians ingested deuterium-labeled l-carnitine (d3-l-carnitine) or γBB (d9-γBB), and both plasma metabolites and fecal polymicrobial transformations were examined at baseline, following oral antibiotics, or following chronic (≥2 months) l-carnitine supplementation. Human fecal commensals capable of performing each step of the l-carnitine→γBB→TMA transformation were identified. RESULTS: Studies with oral d3-l-carnitine or d9-γBB before versus after antibiotic exposure revealed gut microbiota contribution to the initial 2 steps in a metaorganismal l-carnitine→γBB→TMA→TMAO pathway in subjects. Moreover, a striking increase in d3-TMAO generation was observed in omnivores over vegans/vegetarians (>20-fold; P = 0.001) following oral d3-l-carnitine ingestion, whereas fasting endogenous plasma l-carnitine and γBB levels were similar in vegans/vegetarians (n = 32) versus omnivores (n = 40). Fecal metabolic transformation studies, and oral isotope tracer studies before versus after chronic l-carnitine supplementation, revealed that omnivores and vegans/vegetarians alike rapidly converted carnitine to γBB, whereas the second gut microbial transformation, γBB→TMA, was diet inducible (l-carnitine, omnivorous). Extensive anaerobic subculturing of human feces identified no single commensal capable of l-carnitine→TMA transformation, multiple community members that converted l-carnitine to γBB, and only 1 Clostridiales bacterium, Emergencia timonensis, that converted γBB to TMA. In coculture, E. timonensis promoted the complete l-carnitine→TMA transformation. CONCLUSION: In humans, dietary l-carnitine is converted into the atherosclerosis- and thrombosis-promoting metabolite TMAO via 2 sequential gut microbiota-dependent transformations: (a) initial rapid generation of the atherogenic intermediate γBB, followed by (b) transformation into TMA via low-abundance microbiota in omnivores, and to a markedly lower extent, in vegans/vegetarians. Gut microbiota γBB→TMA/TMAO transformation is induced by omnivorous dietary patterns and chronic l-carnitine exposure. TRIAL REGISTRATION: ClinicalTrials.gov NCT01731236. FUNDING: NIH and Office of Dietary Supplements grants HL103866, HL126827, and DK106000, and the Leducq Foundation.


Subject(s)
Atherosclerosis , Betaine/analogs & derivatives , Carnitine/blood , Clostridiales/metabolism , Gastrointestinal Microbiome , Methylamines/metabolism , Animals , Atherosclerosis/metabolism , Atherosclerosis/microbiology , Atherosclerosis/pathology , Betaine/blood , Female , Humans , Male , Mice , Pilot Projects , Vegans
3.
Circ Res ; 123(10): 1164-1176, 2018 10 26.
Article in English | MEDLINE | ID: mdl-30359185

ABSTRACT

RATIONALE: Gut microbes influence cardiovascular disease and thrombosis risks through the production of trimethylamine N-oxide (TMAO). Microbiota-dependent generation of trimethylamine (TMA)-the precursor to TMAO-is rate limiting in the metaorganismal TMAO pathway in most humans and is catalyzed by several distinct microbial choline TMA-lyases, including the proteins encoded by the cutC/D (choline utilization C/D) genes in multiple human commensals. OBJECTIVE: Direct demonstration that the gut microbial cutC gene is sufficient to transmit enhanced platelet reactivity and thrombosis potential in a host via TMA/TMAO generation has not yet been reported. METHODS AND RESULTS: Herein, we use gnotobiotic mice and a series of microbial colonization studies to show that microbial cutC-dependent TMA/TMAO production is sufficient to transmit heightened platelet reactivity and thrombosis potential in a host. Specifically, we examine in vivo thrombosis potential employing germ-free mice colonized with either high TMA-producing stable human fecal polymcrobial communities or a defined CutC-deficient background microbial community coupled with a CutC-expressing human commensal±genetic disruption of its cutC gene (ie, Clostridium sporogenes Δ cutC). CONCLUSIONS: Collectively, these studies point to the microbial choline TMA-lyase pathway as a rational molecular target for the treatment of atherothrombotic heart disease.


Subject(s)
Bacterial Proteins/metabolism , Fecal Microbiota Transplantation , Lyases/metabolism , Platelet Activation , Thrombosis/microbiology , Adult , Animals , Bacterial Proteins/genetics , Choline/metabolism , Clostridium/enzymology , Clostridium/genetics , Female , Gastrointestinal Microbiome , Humans , Lyases/genetics , Male , Methylamines/metabolism , Mice , Mice, Inbred C57BL , Middle Aged , Thrombosis/blood
4.
Heart Fail Clin ; 13(2): 381-401, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28279423

ABSTRACT

Chemotherapy-related cardiac dysfunction (CRCD) has challenged clinicians to hesitate in using cardiotoxic agents such as anthracycline and several protein kinase inhibitors. As early detection of CRCD and timely cessation of cardiotoxic agents became a strategy to avoid CRCD, cardiac troponin and natriuretic peptide are measured to monitor cardiotoxicity; however, there are inconsistencies in their predictability of CRCD. Alternative biomarkers have been researched extensively for potential use as more sensitive and accurate biomarkers. The mechanisms of CRCD and previous studies on traditional and novel biomarkers for CRCD are examined to enlighten future direction of investigation in this combined biology.


Subject(s)
Antineoplastic Agents/adverse effects , Biomarkers/metabolism , Heart Diseases/diagnosis , Neoplasms/drug therapy , Antineoplastic Agents/pharmacology , Early Diagnosis , Heart Diseases/metabolism , Heart Diseases/prevention & control , Humans , Natriuretic Peptide, Brain/metabolism , Neoplasms/metabolism , Translational Research, Biomedical , Troponin T/metabolism
5.
Curr Heart Fail Rep ; 14(2): 106-116, 2017 04.
Article in English | MEDLINE | ID: mdl-28205040

ABSTRACT

INTRODUCTION: Heart failure (HF) is a complex clinical syndrome with diverse risk factors and etiologies, differing underlying pathophysiology, and large phenotypic heterogeneity. RECENT FINDINGS: Advances in imaging techniques coupled with clinical trials that targeted only in those with impaired left ventricular ejection fraction (LVEF) have largely shaped the current management strategy for HF that focuses predominantly in patients with systolic HF. In contrast, there are no effective treatments for HF with preserved ejection fraction (HFpEF). Instead of this "one-size-fits-all" approach to treatment, better precision to define HF phenotypic classifications may lead to more efficient and effective HF disease management. CONCLUSION: Integrating variables-including clinical variables, HF biomarkers, imaging, genotypes, metabolomics, and proteomics-can identify different pathophysiologies, lead to more precise phenotypic classification, and warrant investigation in future clinical trials.


Subject(s)
Heart Failure/classification , Heart Failure/diagnosis , Biomarkers , Forecasting , Heart Failure/therapy , Heart Failure, Systolic/diagnostic imaging , Heart Failure, Systolic/therapy , Humans , Phenotype , Stroke Volume , Ventricular Dysfunction, Left/diagnosis , Ventricular Dysfunction, Left/therapy , Ventricular Function, Left
6.
J Card Fail ; 22(6): 417-22, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26997620

ABSTRACT

OBJECTIVE: To elucidate the prevalence and role of ß1 adrenergic receptor autoantibodies (ß1AR-AAb) belonging to the immunoglobulin (Ig)G3 subclass in patients with heart failure (HF) treated with ß-adrenergic blockers. BACKGROUND: Several cardiac AAbs have been reported to be present in sera from patients with dilated cardiomyopathy and other etiologies. Among AAbs, those recognizing ß1AR-AAbs show agonist-like effects, have detrimental effects on cardiomyocytes, and may induce persistent myocardial damage. METHODS: We quantify total IgG and IgG3 subclass ß1AR-AAb in subjects with chronic stable HF with long-term follow-up. RESULTS: In our study cohort of 121 subjects, non-IgG3-ß1AR-AAb and IgG3-ß1AR-AAb were found to be positive in 20 (17%) and 26 patients (21%), respectively. The positive rate of IgG3-ß1AR-AAb was significantly higher for those with nonischemic compared with ischemic HF etiology (27% vs 8%, P = .01), but the positive rate for non-IgG3-ß1AR-AAb was similar between the 2 groups (18% vs 16%, respectively, P = NS). There were no significant differences in clinical and echocardiographic measures among total ß1AR-AAb negative, non-IgG3-ß1AR-AAb positive, and IgG3-ß1AR-AAb positive groups at baseline. During 2.2 ± 1.2 years of follow-up, we observed similar rates of the composite endpoint of all-cause mortality, cardiac transplantation, or hospitalization resulting from HF between total IgG-ß1AR-AAb negative and positive patients. However, the composite endpoint events were significantly more common in the patients without than in those with IgG3-ß1AR-AAb (P = .048, log-rank test). CONCLUSIONS: Presence of IgG3-ß1AR-AAb, not total IgG, was associated with paradoxically more favorable outcomes in our cohort of patients with chronic systolic HF largely treated by ß-blockers.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Antibodies, Anti-Idiotypic/immunology , Autoantibodies/immunology , Heart Failure, Systolic/drug therapy , Immunoglobulin G/immunology , Receptors, Adrenergic, beta-1/immunology , Antibodies, Anti-Idiotypic/blood , Autoantibodies/blood , Enzyme-Linked Immunosorbent Assay , Female , Heart Failure, Systolic/blood , Heart Failure, Systolic/immunology , Humans , Male , Middle Aged , Prognosis , Prospective Studies , Receptors, Adrenergic, beta-1/blood , Time Factors
7.
Curr Heart Fail Rep ; 13(2): 103-9, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26886380

ABSTRACT

Recent years have brought interesting insights into the human gut microbiota and have highlighted its increasingly recognized impact on cardiovascular (CV) diseases, including heart failure (HF). Changes in composition of gut microbiota, called dysbiosis, can trigger systemic inflammation, which is known to be involved in the pathophysiology of HF. Trimethylamine N-oxide (TMAO), which is derived from gut microbiota metabolites of specific dietary nutrients, has emerged as a key contributor to cardiovascular disease pathogenesis. Elevated TMAO levels have been reported to be associated with poor outcomes in patients with both HF and chronic kidney disease (CKD). Dysbiosis of gut microbiota can contribute to higher levels of TMAO and the generation of uremic toxins, progressing to both HF and CKD. Therefore, this bidirectional relationship between HF and CKD through gut microbiota may be a novel therapeutic target for the cardiorenal syndrome. However, the mechanisms by which gut microbiota could influence the development of heart failure are still unknown, and there are still some questions regarding the causative effects of TMAO and the underlying mechanistic link that explains how TMAO might directly or indirectly promote CV diseases including HF. Further studies are warranted to clarify the function of TMAO on the pathophysiology of cardiorenal syndrome and the handling of TMAO levels by the kidneys.


Subject(s)
Gastrointestinal Microbiome/physiology , Heart Failure/physiopathology , Cardio-Renal Syndrome/metabolism , Cardio-Renal Syndrome/physiopathology , Heart Failure/microbiology , Heart Failure/virology , Humans , Methylamines/metabolism , Microbiota/physiology
8.
Curr Diab Rep ; 15(9): 63, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26208694

ABSTRACT

What we understand about diabetes from decades of genetics research is now being supplemented with exciting new evidence based on a better understanding of how one of the biggest "environmental" factors the body is exposed to is influencing the pathogenesis of disease. The recent discovery that certain dietary nutrients possessing a trimethylamine (TMA) moiety (namely choline/phosphatidylcholine and L-carnitine) participate in the development of atherosclerotic heart disease has renewed attention towards the contributions of gut microbiota in the development of cardiovascular diseases. Collectively, animal and human studies reveal that conversion of these nutrient precursors to trimethylamine N-oxide (TMAO) depends on both microbial composition and host factors, and can be induced by dietary exposures. In addition, circulating TMAO levels are strongly linked to cardiovascular disease risks and various adverse cardio-renal consequences. Our group and others have further demonstrated that circulating TMAO levels are elevated in patients with type 2 diabetes mellitus compared to healthy controls and gut microbiota-dependent phosphatidylcholine metabolism has been implicated in metabolic dysregulation and insulin resistance in animal models. Therefore, preventive strategies to minimize adverse consequences associated with TMAO generation in the diabetic population are warranted.


Subject(s)
Cardiovascular Diseases/microbiology , Diabetes Mellitus/microbiology , Gastrointestinal Microbiome , Animals , Diet , Humans , Methylamines/metabolism , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...